Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium. [electronic resource]
Producer: 20010531Description: 46-54 p. digitalISSN:- 1522-8517
- Adult
- Animals
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Agents, Alkylating -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Blood-Brain Barrier -- drug effects
- Bone Marrow Diseases -- chemically induced
- Bone Marrow Transplantation
- Brain Neoplasms -- drug therapy
- Buthionine Sulfoximine -- pharmacology
- Child
- Clinical Trials as Topic -- methods
- Clinical Trials, Phase III as Topic
- Cognition Disorders -- etiology
- Combined Modality Therapy
- Cranial Irradiation
- Dose-Response Relationship, Drug
- Drug Synergism
- Genetic Therapy
- Genetic Vectors -- pharmacokinetics
- Glioma -- drug therapy
- Glutathione -- metabolism
- Guinea Pigs
- Hearing Loss, Sensorineural -- chemically induced
- Hematopoietic Stem Cell Transplantation
- Humans
- Hypertonic Solutions -- pharmacology
- Lymphoma, Non-Hodgkin -- drug therapy
- Meningeal Neoplasms -- drug therapy
- Multicenter Studies as Topic -- methods
- Neuroblastoma -- drug therapy
- Oligodendroglioma -- drug therapy
- Permeability -- drug effects
- Quality of Life
- Randomized Controlled Trials as Topic -- methods
- Treatment Outcome
No physical items for this record
Publication Type: Congress; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.